DBV Technologies Market Cap ($635.40 Million)
Market Cap & Net Worth: DBV Technologies (DBVT)
DBV Technologies market cap. DBV Technologies (NASDAQ:DBVT) has a market capitalization of $635.40 Million ($635.40 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10689 globally and #2848 in its home market, demonstrating a 1.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DBV Technologies's stock price $10.11 by its total outstanding shares 62848497 (62.85 Million). Also see cash flow conversion of DBV Technologies for how efficiently the company converts equity into cash flow.
DBV Technologies Market Cap History (2015–2026)
DBV Technologies market cap history from 2015 to 2026. Data shows change from $22.82 Billion to $635.40 Million (-27.16% CAGR). Check DBVT stock price and chart for real-time trading data and today's change.
Index Memberships
DBV Technologies is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.02% | #298 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1111 of 3165 |
Weight: DBV Technologies's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DBV Technologies Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DBV Technologies's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of DBV Technologies to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
75.62x
DBV Technologies's market cap is 75.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $22.08 Billion | $7.93 Million | -$126.35 Million | 2785.25x | N/A |
| 2017 | $15.46 Billion | $11.52 Million | -$177.20 Million | 1342.19x | N/A |
| 2018 | $4.03 Billion | $12.81 Million | -$190.26 Million | 314.86x | N/A |
| 2019 | $6.72 Billion | $14.71 Million | -$172.01 Million | 457.22x | N/A |
| 2020 | $1.65 Billion | $11.28 Million | -$159.56 Million | 146.03x | N/A |
| 2021 | $1.01 Billion | $5.71 Million | -$97.81 Million | 176.17x | N/A |
| 2022 | $961.58 Million | $4.84 Million | -$96.27 Million | 198.51x | N/A |
| 2023 | $598.82 Million | $15.73 Million | -$72.73 Million | 38.07x | N/A |
| 2024 | $194.20 Million | $2.57 Million | -$113.72 Million | 75.62x | N/A |
Competitor Companies of DBVT by Market Capitalization
Companies near DBV Technologies in the global market cap rankings as of November 4, 2026. Also see total assets of DBV Technologies for a full breakdown of the balance sheet.
Key companies related to DBV Technologies by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of DBV Technologies (2015–2026)
Market capitalization of DBV Technologies from 2015 to today. Between 2015 and today, DBV Technologies's market cap moved from $22.82 Billion to $ 635.40 Million, with a yearly change of -27.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $635.40 Million | -47.26% |
| 2025 | $1.20 Billion | +520.39% |
| 2024 | $194.20 Million | -67.57% |
| 2023 | $598.82 Million | -37.73% |
| 2022 | $961.58 Million | -4.38% |
| 2021 | $1.01 Billion | -38.93% |
| 2020 | $1.65 Billion | -75.51% |
| 2019 | $6.72 Billion | +66.67% |
| 2018 | $4.03 Billion | -73.90% |
| 2017 | $15.46 Billion | -29.97% |
| 2016 | $22.08 Billion | -3.25% |
| 2015 | $22.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of DBV Technologies was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $635.40 Million USD |
| MoneyControl | $635.40 Million USD |
| MarketWatch | $635.40 Million USD |
| marketcap.company | $635.40 Million USD |
| Reuters | $635.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more